is toujeo a glp-1 These highlights do not include all the information needed to use TOUJEO® U-300 safely and effectively. See full prescribing information for TOUJEO® U-300. U-300 (insulin glargine) injection, for subcutaneous use Initial Toujeo for the Treatment of

The dual effect of managing weight and blood glucose levels enhances the overall metabolic health of individuals, making GLP-1 agonists a highly valuable treatment of obesity and associated metabolic conditions

Heres how to make those self-injections as simple and painless as possible

A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society explicitly states that restrictive eating disorder is a general contraindication to GLP-1 use and that individuals with a history of eating disorders should be referred to an eating disorders specialist before these medications are prescribed ( Mozaffarian et al., Am J Clinical Nutrition, 2025 )

Conflicting Data: While some clinical trials suggested a minor increase in risk, many large-scale "real-world" studies have found no statistically significant difference in pancreatitis risk when comparing GLP-1 users to those on other diabetes treatments

Lancet Diabetes Endocrinol 2021;9:825-36.ArticlePubMed 129

Liraglutide treatment in 5xFAD mice improved spatial memory, an effect associated with enhanced aerobic glycolysis in astrocytes which improved cell support, promoting neuronal survival [51]